The FDA has approved Eli Lilly's Alzheimer's drug Kisunla (donanemab) for mild or early cases of the disease.

Donanemab targets amyloid protein buildup in the brain and has been shown to slow cognitive decline by 39%, providing patients more independence for four to seven months.

The drug is administered through monthly IV infusions and is designed for finite treatment, allowing patients to stop and restart based on amyloid levels.

Pricing for Kisunla varies based on treatment duration, with potential cost savings from shorter treatment cycles.

The drug's convenience, potential cost savings, and safety profile make it a promising option for patients, with early intervention potentially leading to a 90% slowing of cognitive decline.

Challenges remain in identifying patients early and monitoring treatment effectiveness, but future treatments may target multiple proteins involved in Alzheimer's for more comprehensive care.

Regular monitoring for side effects and tailoring treatments to individual patients are crucial for optimal outcomes.